Trial intelligence / Profile preview

Hydroxychloroquine + erlotinib in stage IV non-squamous NSCLC

NL-OMON37508Phase 2Active, not recruiting

Sponsor
VU University Medical Center
Start
May 2012
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of hydroxychloroquine and erlotinib in non-small cell lung cancer (NSCLC), sponsored by VU University Medical Center. Started May 2012; status: active, not recruiting.

02

Drugs

hydroxychloroquineerlotinib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NL-OMON37508.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON37508.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call